Five-year safety and efficacy of belatacept in renal transplantation - Wikidata - wikimedia - TriplyDB

Five-year safety and efficacy of belatacept in renal transplantation

Five-year safety and efficacy of belatacept in renal transplantation

http://www.wikidata.org/entity/Q34621558

about

Belatacept for kidney transplant recipients Belatacept for the prophylaxis of organ rejection in kidney transplant patients: an evidence-based review of its place in therapy Fc-fusion proteins and FcRn: structural insights for longer-lasting and more effective therapeutics Biologics in renal transplantation Haptoglobin enhances cardiac transplant rejection Does belatacept improve outcomes for kidney transplant recipients? A systematic review CTLA4-Ig in combination with FTY720 promotes allograft survival in sensitized recipients.Candida-elicited murine Th17 cells express high Ctla-4 compared with Th1 cells and are resistant to costimulation blockade High CTLA-4 expression on Th17 cells results in increased sensitivity to CTLA-4 coinhibition and resistance to belatacept Costimulatory pathways in transplantation.Belatacept: a new biologic and its role in kidney transplantation.Belatacept : a new biological agent for maintenance immunosuppression in kidney transplantation.Switching from calcineurin inhibitor-based regimens to a belatacept-based regimen in renal transplant recipients: a randomized phase II study The effects of Cyclosporine A and azathioprine on human T cells activated by different costimulatory signals Down-Regulation of Surface CD28 under Belatacept Treatment: An Escape Mechanism for Antigen-Reactive T-Cells CD28 family and chronic rejection: "to belatacept...And beyond!".Cutting Edge: CTLA-4Ig Inhibits Memory B Cell Responses and Promotes Allograft Survival in Sensitized Recipients.Functional Characteristics of C-terminal Lysine to Cysteine Mutant Form of CTLA-4Ig.Identification and characterization of kidney transplants with good glomerular filtration rate at 1 year but subsequent progressive loss of renal function.2B4 (CD244) induced by selective CD28 blockade functionally regulates allograft-specific CD8+ T cell responses.Ten years experience with belatacept-based immunosuppression after kidney transplantation.Immunosuppression for in vivo research: state-of-the-art protocols and experimental approaches.Interruption of OX40L signaling prevents costimulation blockade-resistant allograft rejection.Evaluation of the novel protein kinase C inhibitor sotrastaurin as immunosuppressive therapy after renal transplantation.Profile of belatacept and its potential role in prevention of graft rejection following renal transplantation Belatacept: a novel biologic for maintenance immunosuppression after renal transplantation.Current landscape for T-cell targeting in autoimmunity and transplantation.Belatacept: from rational design to clinical application.Role of regulatory T cells in the promotion of transplant tolerance.Anemia and erythrocytosis in patients after kidney transplantation.Belatacept: in adult kidney transplant recipients.An evaluation of sirolimus in renal transplantation.Belatacept: a new era of immunosuppression?Costimulation blockade: current perspectives and implications for therapy.Belatacept for prevention of acute rejection in adult patients who have had a kidney transplant: an update.The role of belataceptin transplantation: results and implications of clinical trials in the context of other new biological immunosuppressant agents.Belatacept utilization recommendations: an expert position.Risk evaluation and mitigation strategies: a focus on belatacept.Pathophysiology and treatment options of chronic renal allograft damage.Hypertension after kidney transplantation: a pathophysiologic approach.

P2860

Q24187867-AEA7A01A-70AF-4B38-A0EB-A5BCE7D66B8A Q26745773-FE819890-94D0-40CE-ADC0-B894C53496BD Q26822421-6580FA98-88D9-4981-8269-FEBFCA444CFF Q27009997-2EC0B900-D159-4FC7-A634-814DD346A1B8 Q27339208-85AD7D22-6AEA-4CE9-A181-A9CC466CC4E0 Q28084644-BF6FDAD3-59AC-4C87-AC95-75476807456C Q33631095-9F6D4FC7-008C-4887-A44C-92457E4F9081 Q33809102-586A8DFA-92F7-405B-8E3C-559247FD440F Q34014967-2C26D184-9559-499F-B522-A7F8E0CE1985 Q34187594-C750F3BE-120F-4D85-A36D-354890C1136F Q34634807-D0D2E507-01E1-481B-9962-27F8983F6F1F Q34638056-933A2633-7161-4022-AD55-1B0547918EF5 Q34639752-05469FD4-89C1-4D37-9ED3-3827E51B8188 Q35191057-BD5A102C-373B-4EB3-8D99-4D3CE2A9620C Q35937227-C3423E85-0B3D-4091-AD90-C366E2929F33 Q36037639-F56EBE1C-1867-4B9E-AA1E-7B5E620CE4A7 Q36176992-25413585-555B-42AD-84F2-4357214CE276 Q36714916-ABB33256-B07F-4E2B-BA95-DA2B7800124C Q37535280-62B56315-B5A3-48F8-BE0F-78740A359C9E Q37576726-B8BD686B-5056-422A-84F8-37251B07762E Q37604599-B8B78A1D-AED2-4A8E-9EFE-E5E0E4650754 Q37634944-B6A7EC93-DFEB-4D57-9497-BD10C49E049D Q37677433-D7EFD6EC-F40D-4AF2-8D4C-707A7509D27D Q37818197-ECDC2546-1B76-4F4B-82BB-B2C26426BBB1 Q37820147-FD865C24-8379-4050-B5EA-57F6C3D42B2B Q37859368-051490D5-7663-4C1D-A9B9-7BDE117432A3 Q37900647-2D47230B-531D-418A-B574-D690FFA7430D Q37965932-2A94BECF-5057-4A27-AC6D-AB40FF00600D Q38004403-2F91256C-FD22-4FA7-ABEB-E1CB0590F602 Q38020205-73A33529-98CA-49E4-B5F4-CA41A0C05026 Q38038669-80266FDC-EDC6-4756-8B12-71EB28DDC22D Q38038696-2AB333D0-C9AB-4B84-BBAB-CF906F310950 Q38044759-2BBEE542-5ED3-413D-BEFA-5206C6A63A90 Q38057977-222E0F47-8E35-4A49-B449-DC089887663F Q38059865-7E828D2D-22AD-4CFE-9F8F-253C4182B26C Q38063962-6EAA4294-5024-4CC5-AF95-98E0F2BB0A09 Q38064538-6CF30F1A-6495-476D-A4EC-A8EA4754FC24 Q38085439-FECDF927-5B44-48DC-B3BF-45DD8E871295 Q38102662-44EE1D6F-8619-4168-8585-3EB7EF61010E Q38128162-A97C75C2-E1BD-41AF-A62B-701D4E9B8FB3

P2860

Five-year safety and efficacy of belatacept in renal transplantation

http://www.wikidata.org/entity/Q34621558

description

2010 nî lūn-bûn

@nan

2010 թուականի Յուլիսին հրատարակուած գիտական յօդուած

@hyw

2010 թվականի հուլիսին հրատարակված գիտական հոդված

@hy

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

name

Five-year safety and efficacy of belatacept in renal transplantation

@ast

Five-year safety and efficacy of belatacept in renal transplantation

@en

Five-year safety and efficacy of belatacept in renal transplantation

@nl

type

label

Five-year safety and efficacy of belatacept in renal transplantation

@ast

Five-year safety and efficacy of belatacept in renal transplantation

@en

Five-year safety and efficacy of belatacept in renal transplantation

@nl

prefLabel

Five-year safety and efficacy of belatacept in renal transplantation

@ast

Five-year safety and efficacy of belatacept in renal transplantation

@en

Five-year safety and efficacy of belatacept in renal transplantation

@nl

P1433

Q34621558-4B838C53-6F08-4616-9D9A-C4BD4FFA4B49

P1476

Q34621558-D1CD3C07-35F2-4C26-A0F2-94C5657DDEF0

P2093

Q34621558-03E9455F-04B6-4411-9153-817121F8FA29

Q34621558-06703F8E-4270-4819-8362-29978BB9DCA8

Q34621558-14236FFB-7807-46ED-A6E3-AFEA2E9A1700

Q34621558-3F402B46-4DF0-4928-80A4-250F9ABAF1B6

Q34621558-40B1E27D-7370-4C60-AF7D-ED09998A2F6E

Q34621558-4FA6FD93-3E38-4E0A-8C0B-A7AE5830F024

Q34621558-4FD87394-3B26-42D6-87F9-FA9C2FF61E09

Q34621558-624F1360-E2B6-4EDC-A031-A739A8F04475

Q34621558-648F58A6-D7EA-4930-9C8E-36E61EBF93AC

Q34621558-7219340B-7A0E-4E26-A5DE-6C1E0D09245A

P2860

Q34621558-0030328F-C6BF-48BD-A0E7-9A8DBB8827CB

Q34621558-0EA6332A-F0A9-4819-8C7E-F0C354E6CFBD

Q34621558-2CE566CA-67E4-41B2-9025-4DDD06E118A6

Q34621558-35287D0B-2FF4-44C7-9B9E-E77EAA240AAC

Q34621558-3EFE5EE2-CB08-4AF9-BF83-16F870546214

Q34621558-49DB4022-EA31-4DA7-98AF-0B356EA26DB0

Q34621558-59CE0BD7-9C4A-4F48-97EB-1B81AE2CD3E1

Q34621558-755B4AC3-C4F0-4480-9BAD-C5651F3B551E

Q34621558-8D6A60F9-CAD7-452D-B925-42234190C170

Q34621558-9515CDD0-4276-4039-9D65-B7A51A725DAA

P304

Q34621558-3C2FA8AA-0FA0-44F2-89A9-A485C220D943

P31

Q34621558-0A7DFB8A-BCB6-40F5-B545-A897127F939C

P356

Q34621558-48B7E5BA-2DBE-49AB-9AA5-BD8D3978F66D

P433

Q34621558-A698BCA9-76D2-439A-94DC-31BBF7E180A3

P478

Q34621558-EE1CB32F-C261-4818-8286-5FBE4393CCBD

P50

Q34621558-F8976F51-B19A-445F-8B74-C66D8AAD9187

P577

Q34621558-578332CA-4835-4B76-8B29-0B60CD7F17C7

P698

Q34621558-ABEDCDBD-A02B-4427-9448-5129F8174216

P932

Q34621558-0568D6F9-31D0-4A40-A46F-D162354FEBE2

P356

P1433

Journal of the American Society of Nephrology

P1476

Five-year safety and efficacy of belatacept in renal transplantation

@en

P2093

Antoine Durrbach

http://www.w3.org/2001/XMLSchema#string

Bernard Charpentier

http://www.w3.org/2001/XMLSchema#string

Björn Nashan

http://www.w3.org/2001/XMLSchema#string

Christian P Larsen

http://www.w3.org/2001/XMLSchema#string

Ferdinand Mühlbacher

http://www.w3.org/2001/XMLSchema#string

Flavio Vincenti

http://www.w3.org/2001/XMLSchema#string

Gilles Blancho

http://www.w3.org/2001/XMLSchema#string

Jinshan Shen

http://www.w3.org/2001/XMLSchema#string

Josep Grinyo

http://www.w3.org/2001/XMLSchema#string

Jurgen Klempnauer

http://www.w3.org/2001/XMLSchema#string

P2860

Strategies to improve long-term outcomes after renal transplantation.

Cardiovascular toxicities of immunosuppressive agents.

Polyomavirus in renal transplantation: a hot problem.

Reassessing the impact of cytomegalovirus infection in kidney and kidney-pancreas transplantation.

A long-term comparison of tacrolimus (FK506) and cyclosporine in kidney transplantation: evidence for improved allograft survival at five years.

A phase III study of belatacept-based immunosuppression regimens versus cyclosporine in renal transplant recipients (BENEFIT study).

Predicting kidney graft failure using time-dependent renal function covariates.

Herpes zoster infection following solid organ transplantation: incidence, risk factors and outcomes in the current immunosuppressive era.

Performance of different prediction equations for estimating renal function in kidney transplantation.

Calcineurin inhibitor minimization in the Symphony study: observational results 3 years after transplantation.

P304

1587-1596

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1681/ASN.2009111109

http://www.w3.org/2001/XMLSchema#string

P433

9

http://www.w3.org/2001/XMLSchema#string

P478

21

http://www.w3.org/2001/XMLSchema#string

P50

Jean-Paul Soulillou

P577

2010-07-15T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

20634298

http://www.w3.org/2001/XMLSchema#string

P932

3013525

http://www.w3.org/2001/XMLSchema#string